Olaparib: The first PARP inhibitor to gain approval, olaparib, has been extensively studied and is approved for use as maintenance therapy in patients with recurrent ovarian cancer, regardless of BRCA mutation status. This evidence concerns the gene PARP1 and ovarian carcinoma.